Myotonia Congenita, Myotonic Disorders, Nondystrophic Myotonias
Conditions
Keywords
Myotonia, Paramyotonia Congenita, Thomsen's Disease
Brief summary
Nondystrophic myotonias (NDM) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. Individuals with NDM experience limited muscle relaxation, which causes pain, weakness, and impaired physical activity. The purpose of this study is to better characterize the clinical features and symptoms of NDM.
Detailed description
Nondystrophic myotonias are muscle disorders caused by abnormal muscle cell membrane proteins that affect the control of muscle fiber contraction. These disorders are extremely rare, and little is known about how to best treat the various subtypes of NDM. The purpose of this study is to characterize the clinical features and symptoms of NDM as well as to pair this data with specific NDM subtypes. In turn, this may lead to the development of improved treatments. The study will also establish clinical endpoints for use in future studies. This multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. Participants will initially attend a one-day outpatient study visit. Various baseline measurements will be collected, including demographics, medical history, and quality of life measures. Blood samples will be taken to evaluate laboratory values and genetic factors. Participants will undergo manual muscle testing (MMT), clinical myotonia assessments, and functional movement assessments. Routine nerve conduction studies and electromyography (EMG) will also be performed in order to test for the presence of myotonia in specific muscles. Annual follow-up evaluations will occur 1 and 2 years following the first study visit.
Interventions
None listed
Sponsors
Office of Rare Diseases (ORD)
Rare Diseases Clinical Research Network
Richard Barohn, MD
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical symptoms or signs suggestive of myotonia * Presence of myotonic potentials on electromyography (EMG) * Persistence of symptoms and signs after discontinuation of medications that produce myotonia; such medications include fibric acid derivatives, hydroxymethylglutaryl CoA reductase inhibitors, chloroquine, and colchicine * Absence of features suggestive of myotonic dystrophy, including ptosis, temporal wasting, mandibular weakness, cataracts occurring before age 50, and evidence of multisystem defects (cardiac conduction defects, hypogonadism)
Exclusion criteria
* Any other neurologic condition that might affect the assessment of the study measurements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Examine the frequency applicable events related to Nondystrophic Myotonia | Baseline - 3 yrs | We will measure by an interactive voice response to measure stiffness, pain, weakness, and fatigue. |
Countries
Canada, United Kingdom, United States
Outcome results
None listed